|
Heart failure
|
0.500 |
Biomarker
|
disease |
RGD |
Serotonin responsiveness through 5-HT2A and 5-HT4 receptors is differentially regulated in hypertrophic and failing rat cardiac ventricle.
|
17936780 |
2007 |
|
Heart failure
|
0.500 |
Biomarker
|
disease |
CTD_human |
Accordingly, antagonists of 5-HT(2B) receptors might represent novel therapeutics for sympathetic overstimulation-dependent heart failure.
|
19023134 |
2009 |
|
Heart Failure, Right-Sided
|
0.310 |
Biomarker
|
disease |
CTD_human |
Serotonin and angiotensin receptors in cardiac fibroblasts coregulate adrenergic-dependent cardiac hypertrophy.
|
19023134 |
2009 |
|
Heart Failure, Right-Sided
|
0.310 |
Biomarker
|
disease |
BEFREE |
Furthermore, right ventricle-targeted therapies, aimed at mitigating the effects of functional right ventricular failure, include β-adrenoceptor (β-AR) blockers, angiotensin-converting enzyme (ACE) inhibitors, antioxidants, modulators of metabolism, and 5-hydroxytryptamine-2B (5-HT2B) receptor antagonists.
|
26583148 |
2015 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine.
|
10617681 |
2000 |
|
Heart valve disease
|
0.500 |
Therapeutic
|
group |
RGD |
Therefore, we sought to determine whether cyproheptadine, a 5-HT(2B)R antagonist, might prevent toxic valvulopathy in an animal model of pergolide-induced valvular heart disease.
|
19346455 |
2009 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
[Pergolide associated valvulopathy: critical analysis of the literature and practical recommendations].
|
16141947 |
2005 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
A more likely cause of fenfluramine-induced valvulopathy is activation of 5-HT(2B) receptors on heart valves by the metabolite norfenfluramine.
|
19505264 |
2009 |
|
Heart valve disease
|
0.500 |
Biomarker
|
group |
CTD_human |
Our data imply that activation of 5-HT(2B) receptors is necessary to produce VHD and that serotonergic medications that do not activate 5-HT(2B) receptors are unlikely to produce VHD.
|
11104741 |
2000 |
|
Heart Valve Prolapse
|
0.200 |
Therapeutic
|
disease |
RGD |
Cyproheptadine prevents pergolide-induced valvulopathy in rats: an echocardiographic and histopathological study.
|
19346455 |
2009 |
|
Hormone refractory prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In this study, we evaluated the expression of 5-HTR2B and 5-HTR4 in HRPC, and the effects of their antagonist on PC cell line growth.
|
15925089 |
2005 |
|
Hyperalgesia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
RVM microinjection of the CCK2 receptor agonist CCK-8 and intrathecal injection of the 5-HT2B receptor agonist BW723C86 both produced hyperalgesia in female rats after plantar incision, whereas the CCK2 receptor antagonist YM022, the 5-HT2B receptor antagonist RS127445, and the PKCγ inhibitor C37H65N9O13 decreased the rats' sensitivity to the same stimulus.
|
31308730 |
2019 |
|
Hyperinsulinism
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The HTR2B Q20* allele and testosterone predicted lower BMI independently, but an interaction between HTR2B Q20* and testosterone lead to increased insulin sensitivity among HTR2B Q20* carriers with low testosterone levels.
|
27420381 |
2016 |
|
Hypersensitivity
|
0.010 |
Biomarker
|
group |
LHGDN |
5-HT(2B) receptors play a key role in mediating the excitatory effects of 5-HT in human colon in vitro.
|
11877320 |
2002 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
CTD_human |
The 5-hydroxytryptamine2B receptor and 5-HT receptor signal transduction in mesenteric arteries from deoxycorticosterone acetate-salt hypertensive rats.
|
8627522 |
1996 |
|
Hypertensive disease
|
0.320 |
Biomarker
|
group |
BEFREE |
Also, the involvement of the 5-HT2B receptor in the vascular growth often observed in hypertension is likely.
|
11378296 |
2001 |
|
Hypertensive disease
|
0.320 |
AlteredExpression
|
group |
BEFREE |
These data show that activation of 5-HT(2B) receptors is a limiting step in the development of pulmonary hypertension.
|
12244304 |
2002 |
|
Hypertrophic Cardiomyopathy
|
0.200 |
Biomarker
|
disease |
MGD |
|
|
|
|
Idiopathic pulmonary arterial hypertension
|
0.020 |
Biomarker
|
disease |
BEFREE |
Loss of serotonin 5-HT(2B) receptor function may predispose to fenfluramine-associated PPH in man.
|
14659797 |
2003 |
|
Idiopathic pulmonary arterial hypertension
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Thus, we demonstrate that activation of 5-HT(2B) receptors on bone marrow lineage progenitors is critical for the development of PAH.
|
22186990 |
2012 |
|
Idiopathic pulmonary hypertension
|
0.010 |
Biomarker
|
disease |
BEFREE |
Loss of serotonin 5-HT(2B) receptor function may predispose to fenfluramine-associated PPH in man.
|
14659797 |
2003 |
|
Impulsive Behavior
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
Our study shows the potential for identifying and tracing effects of rare alleles in complex behavioural phenotypes using founder populations, and indicates a role for HTR2B in impulsivity.
|
21179162 |
2010 |
|
Impulsive Behavior
|
0.080 |
GeneticVariation
|
phenotype |
BEFREE |
Regression analyses showed that among the HTR2B Q20* carriers, temperamental traits resembled a passive-dependent personality profile, and the presence of the HTR2B Q20* predicted impulsive and aggressive behaviors particularly under the influence of alcohol.
|
26575222 |
2015 |
|
Impulsive Behavior
|
0.080 |
GeneticVariation
|
phenotype |
BEFREE |
No association between suicides and MAOA-uVNTR and HTR2B Q20*, which have been previously connected to violent and impulsive behavior, was detected.
|
28608626 |
2017 |
|
Impulsive Behavior
|
0.080 |
Biomarker
|
phenotype |
BEFREE |
A priori evidence linked HTR2B to impulsivity/aggression but not to cannabis response.
|
29875475 |
2018 |